The hepatitis E virus (HEV) -discovered as the cause of a hepatitis epidemic in the early 1980s 1 -is one of five known human hepatitis viruses, to which the hep atitis B virus and hepatitis C virus also belong. Molecular character ization has revealed that there are several geno types 2 . HEV genotype 1 (HEV1), HEV2, HEV3 and HEV4 are responsible for most infections in humans (TABLE 1) . HEV1 and HEV2 are endemic in developing regions, are responsible for large outbreaks and cause severe hepatitis if infection occurs during pregnancy 3 . By contrast, HEV3 and HEV4 are mainly observed in developed regions and are zoonotic, with pigs being the main reservoir. HEV usually spreads to humans through the food chain via faecal contamination of drinking water or consumption of meat from infected animals, but iatrogenic transmis sion is also possible. Infection with the virus causes hep atitis E, which usually presents as an acute, selflimiting form of liver inflammation. However, acute hepatitis can progress to chronic hepatitis, cirrhosis, liver failure and acuteonchronic liver failure. Over the past decade, interest in HEV infection has increased after the descrip tion of cases of chronic hepatitis in immunosuppressed individuals (for example, after organ transplantation) in the developed world, reports of severe HEVassociated extrahepatic manifestations (such as neurological injur ies) and the presence of HEV in blood products used for transfusion 2, 4 . In this Primer, we describe the current knowledge about HEV pathophysiology and transmis sion as well as the epidemiology, clinical manifestations, diagnosis and management of HEV infection.
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Epidemiology
The seroprevalence rate of antiHEV antibodies can be used as a marker for present and past infections. However, the use of different serological assays with different sensitivities has caused considerable variation between studies estimating seroprevalence, which has made estimation of the true seroprevalence difficult. Newer, moresensitive assays generally produce higher estimates of antiHEV immunoglobulin G (IgG) sero prevalence than older, commercially available assays, as highlighted in a metaanalysis 5 . Nevertheless, the high clinical sensitivity of the newer assays does not reflect poor specificity 6 .
Developing regions
Hepatitis E is highly endemic in several parts of Asia (south, central and southeast Asia), Africa, the Middle East and Mexico 7 (FIG. 1) . In these areas, HEV1 and HEV2 are the most prevalent genotypes and infections are usually spread through contamination of the water supplies with human faeces 2, 8 . HEV1 is most wide spread; HEV2 has been reported only in Africa and during one outbreak in Mexico in the 1980s (FIG. 1) . Mathematical modelling has shown that HEV1 and HEV2 cause an estimated 20.1 million (95% credible interval of 2.8-37.0 million) new infections annually in Asia and Africa, with 3.4 million (95% credible inter val of 0.5-6.5 million) cases of acute hepatitis E, 70,000 (95% credible interval of 12,400-133,000) deaths from acute liver failure and 3,000 (95% credible interval of 1,900-4,400) stillbirths 9 . Adolescents and young adults are especially prone to developing hepatitis E, both in epidemic settings and as sporadic cases 10, 11 . HEV infection in children is more often asymptomatic than it is in adults 7 . HEV infection is more common in men than women, possibly because of a greater exposure to contaminated water 7 .
In highly endemic regions, diseases associated with HEV1 or HEV2 infection often occur as outbreaks related to contamination of drinking water supplies, usually following heavy rainfall or flooding 10, 12 . Some outbreaks have also been reported during summer months, when reduced water flow in rivers leads to increased faecal contamination 11 . In Africa, some out breaks have occurred in refugee camps with limited facilities for water hygiene and sanitation 13, 14 . Food borne transmission of HEV, though possible, has not been documented in these areas, possibly owing to the inherent difficulty of establishing a causal association of an illness with food consumed several weeks prior. Persontoperson transmission of HEV1 or HEV2 is infrequent in both sporadic and epidemic settings 15, 16 . In outbreaks in African refugee camps, the occurrence of several cases in one family was suggested to be due to persontoperson transmission 13 but could also be attributed to high disease attack rates (that is, the ratio of the number of people affected to the total number of people residing in the area) resulting from high levels of environmental contamination 17, 18 . However, verti cal transmission of HEV1 and HEV2 from a woman to her child during pregnancy is well documented 19, 20 . Transmission of HEV1 through blood transfusions has also been reported in India 21, 22 . The contribution of these routes to the overall burden of hepatitis E has not been determined but is likely small.
HEV outbreaks vary in size, from small clusters involving a few individuals each to large outbreaks involv ing several thousand individuals, with disease attack rates of up to 15% 10, 11, 23 . The incubation period of HEV infection in outbreaks in which the period of water contamination was known has varied from 2 weeks to 10 weeks 10 . The outbreaks are usually short lived and unimodal 10 . However, some outbreaks -caused by pro longed contamination of drinking water sources -have been multimodal and have lasted for several months 11 . The seroprevalence rate of antiHEV antibodies in most parts of Asia and Africa is 10-40%, with the high est levels in older age groups (>50 years of age) 24 . The seroprevalence of antiHEV antibodies is lower than that of antibodies to other enterically transmitted pathogens, such as hepatitis A virus and Helicobacter pylori 24 . This finding is unexpected, particularly for areas such as the Indian subcontinent where HEV infection is frequent. The reason for this apparent discrepancy is unclear but may be related to the disappearance of antiHEV anti bodies with time. By contrast, antiHEV seroprevalence rates in Egypt are very high (~80%) despite symptomatic hepatitis E being fairly infrequent 25, 26 . The reason for this mismatch between rates of HEVassociated disease and seroprevalence is unclear but could be attributed to crossreactivity of the detected antibodies, sensitivity of previously used antiHEV IgG serological assays, circu lation of lesspathogenic strains of HEV or the failure of the surveillance systems to identify symptomatic hepatitis E.
Developed regions
Hepatitis E in the developed world is mainly caused by infection with HEV3. In some highincome areas in Asia (such as Japan, Taiwan, South Korea and Hong Kong), the disease pattern resembles that of developed regions and is characterized by infection with HEV3 or HEV4 transmitted through animal sources 8 (TABLE 1) .
Furthermore, China has transitioned from having a highendemicity pattern with frequent outbreaks caused by HEV1 to a lowendemicity pattern with sporadic cases of HEV4 infection over the past few decades 27 ; this trend is possibly the consequence of improvements in sanitation. Hepatitis E as a consequence of HEV4 infection is now most commonly observed in middle aged Chinese men 27 . In Japan, HEV4 infection is also endemic 28, 29 (FIG. 1) . All HEV1 infections in Europe and in the United States are travelassociated 30 . The main risk factors for contracting HEV3 or HEV4 are direct contact with infected animals, consumption of HEV contaminated food products (such as undercooked meat) or transfusion of tainted blood products.
Europe. The prevalence of hepatitis E in Europe differs between regions. Although hepatitis E is hyperendemic in southwest France, with seroprevalence rates of >50% 6 , it is endemic in northern France, the United Kingdom, Belgium, the Netherlands, Luxembourg and Germany where 10-30% of individuals have serological evidence of previous HEV exposure 4 . However, the seroprevalence is only 2% in children aged 2-4 years living in southwest France despite the fact that this is a hyperendemic area. Adults in Scotland (as well as in Fiji and New Zealand) have a very low seroprevalence (<5%) 6 . Estimates show that 68,000 HEV infections in France 31 , 100,000 in the United Kingdom 32 and 300,000 in Germany occur annually 33 . A semistructured survey performed in 30 countries in the European Economic Area showed that the number of reported cases of HEV infection has increased from 514 per year in 2005 to 5,617 in 2015, with most infections being locally acquired 34 . In addi tion, 545 hospitalizations and 18 deaths occur per year owing to HEV infection in France 31 . HEV infec tion has become the most frequently diagnosed viral cause of acute hepatitis between 2013 and 2015 in the Netherlands 35 . HEV seroprevalence increases with age, and symptomatic hepatitis E is mainly detected in men ≥50 years of age 36 .
The United States. Studies performed several years ago have documented unexpectedly high rates of HEV antibodies in historical blood samples among US blood donors and the general population 37 . Initial estimates as high as 21% were recently revised to a lower 6% prevalence of antiHEV IgG 38 . Analysis of HEV RNA in ~128,000 plasma samples collected from 96 centres across the United States showed that 0.002% were pos itive 39 . The perplexing infrequency of HEV infection might be explained by the lessfrequent consump tion of game or organ meat in the United States than in Europe 40 . However, the continued absence of a US FDAlicensed assay available to confirm suspected HEV infections combined with a continued lack of knowledge about this virus among clinicians in the United States might also play a part. Age, lower socioeconomic status, foreign birth and consumption of processed meat were identified as risk factors for seropositivity 38 . HIV positiv ity is not associated with increased rates of antiHEV antibodies or chronic HEV infections 41 .
Mechanism/pathophysiology HEV HEV belongs to the genus Orthohepevirus in the Hepeviridae family (https://talk.ictvonline.org). The Orthohepevirus A species includes seven genotypes (HEV1-HEV7), but only one serotype is recognized. The other Orthohepevirus species include avian (Orthohepevirus B) and mammalian (Orthohepevirus C and D) strains that are not transmitted to humans.
HEV is a small RNA virus with an icosahedral capsid, of which two types of fully infectious particles have been described. The virions shed in the faeces are not envel oped (naked HEV particles), are 27-34 nm in diameter and have a density of 1.22 g per ml. The virions circu lating in the blood are cloaked in host cell membranes and have a density of 1.08 g per ml. The hostderived membranes might protect the virus from neutraliza tion by antibodies and could play an important part in cell tropism 42 . Viral genome. The HEV genome is a singlestranded, positivesense RNA of ~7.2 kb consisting of a short 5ʹnoncoding region that is capped with 7methyl guanosine, three open reading frames (ORFs) and a short 3ʹnoncoding region that ends in a poly(A) tail (FIG. 2) .
ORF1 encodes a nonstructural protein of ~1,700 amino acids that is involved in HEV RNA replication (FIG. 2) , which contains several functional domains: a methyltransferase and guanyltransferase, a cysteine protease, a macrodomain (X domain), an RNA heli case that has 5ʹnucleoside triphosphatase activity and an RNAdependent RNA polymerase 43 . The poly proline region is an intrinsically disordered region in which segments of human genes and duplications and/or insertions of parts of ORF1 have been identi fied [44] [45] [46] . Immunocompromised patients who develop chronic infection often harbour a highly heterogeneous population of variants (that is, quasi species) that often differ in the polyproline region 44 . The ORF1 of HEV1 includes an additional ORF, that is, ORF4 (REF. 47 ). ORF4 protein is expressed after endoplasmic reticulum stress and interacts with eukaryotic elongation factor 1α1 to stimulate virus polymerase activity.
ORF2 includes the 660aminoacid virus capsid pro tein. This protein has three glycosylation sites (Asn132, Asn310 and Asn562) and an amino terminal signal peptide that drives its translocation into the endo plasmic reticulum 48 . The capsid protein has been divided into three domains: the shell, middle and protruding domains. The protruding domain is the major target for neutralizing antibodies and contains a putative receptor binding domain 49, 50 . Capsid monomers self assemble to form decamers that encapsulate the viral RNA. The capsid consists of 180 copies arranged as an icosa hedron 51 . Immunological and structural studies of the capsid protein have contributed to the development of a hepatitis E vaccine 52, 53 . Quasispecies present in immuno compromised patients with chronic HEV infec tion are often highly heterogeneous in regions encod ing the middle domain and protruding domain of the capsid protein 54 . ORF3 includes the small ORF3 protein, which is 113 residues in HEV3 and 114 residues in HEV1, HEV2 and HEV4 and is essential for virus egress. ORF3 pro tein is associated with enveloped HEV particles only, not with naked HEV particles. The ORF3 protein must be phosphorylated on Ser80 before it can interact with the nonglycosylated form of the capsid protein 55 . The ORF3 protein contains a conserved proline-serine-alanineproline motif that enables it to interact with the endo somal sorting complex required for transport, including the tumour susceptibility gene 101 protein 56, 57 .
Phylogeny. Phylogenetic analyses of HEV genomes have shed light on evolutionary differences between geno types, which underlie epidemiological and clinical dis parities. HEV seems to have evolved through a series of steps, in which the ancestors of HEV might have adapted to a succession of animal hosts leading to humans 58 . Divergence time analysis showed that the ancestor of the HEVs split into anthropotropic (HEV1 and HEV2) and enzootic genotypes (HEV3 and HEV4) ~536-1,344 years ago 58 . Most of the HEV genome is evolutionarily conserved, but one locus of positive selection encod ing two distinct protein products within the ORF2 and ORF3 overlap region has been identified 59 . HEV1 seems to be evolving differently than HEV3 and HEV4 because HEV3 and HEV4 are unable to achieve the same fitness owing to repeated host jumps 59 . 62 , suggesting that HEV1 and HEV2 cannot cross the species barrier.
Transmission
Although HEV3 and HEV4 infections mainly occur through zoonotic transmission, the viruses have been detected in untreated wastewater, slurry storage facili ties of pig manure and river water 63 . Ingestion of con taminated water might result in infection. Indeed, in France, seroprevalence for antiHEV IgG was associated with eating oysters, whereas drinking bottled water was associated with a lower rate of antiHEV IgG 64 .
Zoonotic transmission. Direct and indirect contact with infected animals or consumption of contaminated food products are the main transmission routes of HEV3 and HEV4 to humans 65 . HEV3 and HEV4 are abundant in HEV genotype HEV1 and HEV2 HEV1 and HEV3 HEV3 HEV3 and HEV4 HEV4 Unknown Nature Reviews | Disease Primers domestic swine from all over the world 65 . In addition, HEV3 RNA, HEV4 RNA or specific antiHEV anti bodies have been detected in a wide range of different animal species such as other Suidae (for example, wild boar 66 ), wild fauna (such as sika deer, red deer, roe deer, mongooses 65 or rabbits 67 ) and domestic animals (such as goats, sheep, buffaloes, yellow cattle, work horses, cats and dogs) 65, 68 , implying that these animals are potential sources of HEV exposure.
HEV3 and HEV4 infection in animals is asympto matic, but the virus is excreted in large quantities in the faeces of infected animals, which contributes to the maintenance of the virus in herds. HEV excretion is the highest in growing pigs of 3-5 months of age 69 . Studies in pig farms demonstrate a very wide spread of the virus worldwide, with 100% of herds contamin ated in several areas of Europe and China 70 . Infected pork liver, pork products containing liver and other pork meat consumed raw or undercooked have been identi fied as sources of HEV infections [71] [72] [73] ; 3-11% of pig liver samples that enter the food chain in developed countries are HEV RNApositive 65 . In addition, HEV3 and HEV4 were also detected in the milk of infected cows 74 .
Personnel with professional occupation with pigs, such as farmers, veterinarians and individuals working in the slaughterhouse, are more frequently HEVseropositive than the general population [75] [76] [77] [78] , as are forestry work ers 79 . The virus is also present in the abattoir environ ment 80, 81 . By contrast, living in a pigrearing area, where farm biosecurity and waste management are controlled, is not associated with increased risk of HEV exposure 82 . In addition to HEV3 and HEV4, other HEV strains and genotypes show occasional zoonotic behaviour. Rabbit HEV, which is closely related to HEV3, circulates in rabbits in China, the United States and Europe 83, 84 . Sequence comparison identified several rabbit HEV strains that infect humans in France, indicating that the rabbit HEV is zoonotic 67, 85 . Rabbit HEV can also cause crossspecies infection in a nonhuman primate and pig models 86, 87 . Furthermore, one case of trans mission of HEV7 to an immunocompromised individual through consumption of camel meat and milk has been described; this individual developed severe hepatitis E and required liver transplantation 88 . Further investigations are needed to evaluate the importance of the camel reservoir as a source for human infections. Finally, HEV5 and HEV6 have been detected in wild boar in Japan, but no infec tion of humans has been described 89 . Other food products are also possible sources of HEV, as HEV3 RNA was detected in red fruits, straw berries, green leaves and spices 65 . HEV bioaccumula tion was demonstrated in oysters under experimental conditions 90 , and HEV RNA was detected in mussels 91 , thereby multiplying potential sources of human expo sure. Whether contamination of vegetables and shellfish contributes to the spread of HEV in animals and humans requires investigation 92 .
Iatrogenic transmission. Although less common than waterborne or zoonotic transmission, HEV can be transmitted iatrogenically between humans through infected blood and blood products. In England, trans fusiontransmitted HEV infection accounts for <1% of all human infections with HEV (the remainder being due to zoonotic transmission); transfusion of 13 blood components from different donors equates to the annual dietary risk of HEV exposure in the general population 93 . Transfusionassociated HEV infection has been docu mented for HEV3 in many European countries 32 , for HEV1 and HEV4 in China 94 and for HEV3 and HEV4 in Japan 95 . Only a minority of recipients of infected blood or blood products develops symptomatic hepatitis E; most iatrogenic transmissions remain asymptomatic. Only when infected blood or blood components are given to immunosuppressed individuals is the risk of developing chronic HEV infection considerable 32 . Iatrogenic infec tion is, therefore, neglected, as infected recipients have no symptoms and develop only minor persistent liver enzyme abnormalities, which might occur only months after infection 95 . Transfusiontransmitted HEV infection has been best documented in England and Japan. A study from 2012 to 2013 in southeast England that involved screening of samples from 225,000 blood donors for HEV RNA showed that 79 donors were viraemic for HEV3 and that 62 infected blood components were used before identifi cation of donor viraemia 32 . Followup of 43 recipients of these blood products revealed that HEV RNA was detected in 18 (42%), which correlated with donor blood samples with high viral loads. Ten of these eighteen individuals were hightomoderately immunosuppressed, which was associated with prolonged HEV viraemia. Three recipients required intervention in the form of lowering the level of immunosuppressive drugs (n = 1) or administration of the antiviral drug ribavirin (n = 2) to successfully achieve viral clearance. The minimum infective dose of HEV levels in blood components to cause infection was 2 × 10 4 IU per ml; HEV infection was observed in 55% of recipients of blood components with at least this dose 32 . In Japan, 20 cases of transfusiontransmitted HEV infection have been documented 95 . An analysis of 19 of these cases, which were caused by HEV3 (n = 17) and HEV4 (n = 2), showed that the minimum infective dose was 3.6 × 10 4 IU per ml, which caused infection in 50% of recipients. Four immuno suppressed patients developed chronic infection Nature Reviews | Disease Primers with evidence of mildtomoderate chronic liver disease, three of whom received ribavirin therapy, with success ful viral clearance in two patients. Presence of antiHEV IgG in recipients does not necessarily protect the recipi ent from transfusiontransmitted infection, as low levels of antibody do not prevent reinfection 96 .
As zoonotic HEV infection is very common in many developed countries and is mostly asymptomatic, HEV has unsurprisingly found its way into the human blood supply. However, what has come as a surprise to many professionals involved in transfusion medicine is the very high frequency of viraemic donors in many countries (TABLE 2) , ranging from 1 per 600 in the Netherlands to 1 per 14,799 in Australia.
Pathophysiology
HEV is a noncytopathic virus. The outcome of acute HEV infection is determined by the strength of the host immune response 97, 98 . HEV pathogenesis consists of three distinct stages: the incubation period, acute hepatitis E (with various clinical phenotypes ranging from asympto matic disease to acute liver failure) and a convalescent phase characterized by a gradual recovery. Although HEV infection is almost always selflimited, persistent, chronic infection can occur in individuals who are immunocompromised. In immunocompro mised pigs infected with HEV, the cellmediated immune response was suppressed, leading to chronic hepatitis and prolonged HEV shedding 99 . HEV multiplies in the liver and reaches the digestive tract via the bile 100 (FIG. 3) . The viral replication in the liver is detectable ~7 days after virus transmission, but the percentage of infected hepatocytes is not known 101 . Although HEV is an hepatotropic virus, immunohisto chemistry experiments and detection of negativesense HEV RNA indicate that replication can also occur in other tissues such as the gastrointestinal tract 67, 102 , kidney 103 , central nervous system 104 and placenta 105 . Infectious HEV virions are secreted by patients with acute hep atitis E into stool and urine 103 . Once HEV infection is cleared, patients have developed immunity against HEV. However, reinfection is possible, although the likelihood of developing symptomatic hepatitis is lower during subsequent infections 106, 107 . (FIG. 4) . HEV RNA becomes detectable in the blood and stool during the incubation period and persists for ~4 weeks and ~6 weeks in blood and faeces, respectively. Capsid antigen persists in the blood for approximately the same duration 109 . An initial incubation period of 2-6 weeks usually precedes the shortlived IgM response, which is detected around the time the levels of liver enzymes, such as serum alanine aminotransferase (a marker of liver inflamma tion or injury), increase and persist for 6-9 months 110 .
The durable IgG response can be delayed, but it persists for several years, although the exact duration of this response remains uncertain. Liver function parameters should be monitored during acute infection. Viral RNA detection and quantification. HEV RNA detection and quantification in blood, faeces or other bodily fluids is the gold standard for detecting an active HEV infection (acute or chronic). DNA primers to detect the presence of HEV RNA are targeted to regions that are conserved across HEV genotypes, usually ORF3 (REFS 116, 117) . Realtime PCR or transcription mediated amplification assays on fully automated plat forms are well adapted for highthroughput testing 118 . The loopmediated isothermal amplification assay prov ides a onestep, singletube amplification of HEV RNA without special equipment 119 . Assays based on RNA amplification all require the WHO international reference panel for validation and comparison of their performance. The limit of detec tion of current assays is 7-80 IU per ml (REFS 116, 118) , which is relevant to take into account not only for diagnosis but also for defining an optimal strategy (testing of individual samples versus minipool testing) for blood screening.
The HEV genotypes and subgenotypes can be character ized by sequencing different regions of the HEV genome, such as the ORF2 region or the ORF1 region encoding RNA polymerase. Sequencing information Nature Reviews | Disease Primers can be used to perform molecular epidemiology to identify the source of infection or to detect mutations in the gene encoding RNA polymerase in patients in whom ribavirin therapy fails 120, 121 . Current studies are examining the prognostic value of these mutations.
Capsid antigen detection. Acute HEV infections can be diagnosed by detecting the HEV capsid antigen via a commercial sandwich enzyme immunoassay. The specificity of this assay is 100%, and the diagnostic sensi tivity for an acute HEV infection is 91%, with no significant difference between immunocompetent (88%) and immunocompromised (94%) patients 122 . As test ing for HEV capsid antigen is technically simpler, less expensive and faster than quantification of HEV RNA levels, this test could become an alternative for diag nosing HEV infections in laboratories with no molecular diagnostic facilities.
Diagnostic algorithm.
When HEV infection is sus pected on the basis of clinical symptoms or an iso lated increase in alanine aminotransferase, antiHEV IgM is measured first, given the good performance and wide availability of this assay (FIG. 5) . Patients who are immunocompromised should be tested for HEV RNA in three clinical settings: when the antiHEV IgM is negative and alanine aminotransferase activity is elevated, when the HEV RNA in blood and stool per sists for 3-6 months (to identify a chronic infection) and when a recent reduction in immunosuppression has been made or antiviral therapy has been started (to monitor chronic infection). Ribavirin therapy is used to obtain HEV clearance. A negative HEV RNA concentration in the faeces is necessary to confirm successful viral clearance 123 . HEV RNA testing can also be useful in immuno competent individuals to confirm ongoing infection in the absence of antiHEV IgM when suspicion for infection is high or to perform viral genotyping.
Hepatic manifestations
In the majority of individuals, HEV infection is asymp tomatic or causes only minor systemic illness without any symptoms related to liver injury. The classic presen tation of hepatitis E -acute icteric hepatitis -occurs in 5-30% of individuals with HEV infection. This pres entation, which lasts 2-6 weeks, consists of a pro dromal phase that lasts up to a week and is characterized by nonspecific symptoms, such as malaise, fever, body aches, nausea and vomiting. The icteric phase is marked by the production of darkcoloured urine and jaun dice. Jaundice and its associa ted symptoms most often resolve spontaneously after a few days to weeks (the convalescent phase). Serum alanine aminotransferase levels are markedly elevated during the pro dromal phase and during the initial part of the icteric phase (FIG. 4) , and bilirubin levels are high during the icteric phase 124 . Importantly, immunocompetent patients with acute hepatitis E usually resolve spontaneously without the need for antiviral therapies.
A small proportion (0.5-4%) of individuals infec ted with HEV develop acute liver failure, which is a lifethreatening condition 125 . The presence of pre existing chronic liver diseases increases the risk of liver failure, with a mortality of up to 67% 126 . Interestingly, patients with acuteonchronic liver failure caused by HEV infection fared better than patients with alcoholassociated acuteonchronic liver failure 127 .
Hepatic manifestations depending on genotype.
The hepatic manifestations following HEV1 and HEV2 infections vary from entirely asymptomatic disease course or mild systemic illness to icteric acute hepatitis and fulminant or acute liver failure (TABLE 1) . Chronic or persistent HEV infection has not been reported follow ing HEV1 and HEV2 infection 128 . Pregnant women, particularly in the second and third trimesters, are at high risk of developing symptomatic disease follow ing HEV1 and HEV2 infections, and a large propor tion of these women progresses to acute liver failure. Thus, mortality in pregnant women with HEV1 and HEV2 infection can be as high as 15-25% 129 . HEV1 and HEV2 infection during pregnancy is also associ ated with an increased risk of adverse outcomes of pregnancy, such as miscarriage, preterm delivery, still birth and perinatal mortality. The newborn babies of these mothers are at risk of acquiring HEV infection through maternal-fetal transmission and of develop ing complications, such as anicteric hepatitis (a mild form of hepatitis without jaundice) or icteric hepatitis, hypoglycaemia and neonatal death 130 .
Infections with HEV3 and HEV4 mostly take a clin ically silent course. Of ~55,000 patients recruited in the placebo arm of the hepatitis E vaccine trial in China who seroconverted to antiHEV antibody positive status, <2% developed symptomatic acute hepatitis 131 . In Europe, 5-33% of patients infected with HEV3 or HEV4 develop symptoms, such as elevated liver enzymes and jaundice 33, 92, 132 . Acute liver failure is rare in patients with HEV3 and HEV4 infections independent of pre existing liver disease, but a few cases have been reported in Europe 31, [133] [134] [135] . Preexisting chronic liver disease might predispose individuals to acuteonchronic liver failure. However, of the 343 patients with decompen sated chronic liver disease studied in Toulouse, France, and in three centres in the United Kingdom, only 11 tested positive for HEV RNA 125 . The mortality did not differ between HEVpositive patients and HEVnegative patients. Similarly, the prevalence of HEV infection in patients with severe forms of acute alcoholic hep atitis was low in France 136 . Thus, HEV infection might not predispose individuals to moresevere liver dis ease, although case reports of the need for liver trans plantation associated with HEV infection have been reported 135 . The association of increased incidence and severity of hepatitis E in pregnant women infected with HEV1 or HEV2 is not observed for HEV3 and HEV4 (REFS 137, 138) .
Immunocompromised individuals. In adults [139] [140] [141] or children 142 who receive immunosuppressive therapy following solid organ transplantation (SOT) or stem cell transplantation 143, 144 , in patients receiving chemo therapy 145 or immunotherapy 146 and in patients with concomitant HIV infection 147 , HEV replication can persist beyond 3-6 months, leading to chronic hep atitis with progressive liver fibrosis and cirrhosis 148 . This disease course of chronic infection has mainly been reported for HEV3 but can also occur for HEV4 (REF. 149) . Chronic hepatitis E is most often reported in patients receiving SOT 141 , with onethird of the patients being able to spontaneously clear the virus and two thirds developing chronic hepatitis 141, 150 . Within a few years after the infection, ~10% of the infected patients developed cirrhosis 141, 151 . Strong immunosuppression is associated with the development of chronic infec tion. Hence, patients receiving SOT who have devel oped chronic hepatitis were more often treated with tacrolimus (a more potent immunosuppressant) than with cyclosporine A 141 , had low lymphocyte subset counts 139, 150 and had lesspronounced antiHEVspecific T cell responses 97 .
The majority of immunosuppressed patients are asymptomatic and present with persistent, mildly abnormal liver function tests 141 . Diagnosis of HEV infection is further complicated by the fact that anti HEV IgG and antiHEV IgM tests may remain negative during and after HEV infection in immunosuppressed patients 141 . Importantly, no HEV reactivation was observed after HEV clearance 152 . However, reinfections have been described and can lead to chronic hepatitis 115 .
Extrahepatic manifestations
Several extrahepatic manifestations have been reported in association with HEV infection
. For most of these conditions, the published data are from single case reports or small case series and causality has not been established. However, there are more data on the neuro logical and renal manifestations associated with HEV infection than with the other conditions; some evidence supports a causal relationship.
Neurological manifestations. HEV infection has been described in association with a range of neurological manifestations [153] [154] [155] 
. To date, >150 cases have been described, mainly associated with HEV3 infec tion in Europe or in the context of HEV1 infection in Asia. More than 90% of cases have been documented in immunocompetent individuals, but neurological manifest ations also occur in the context of chronic infec tion with HEV3 in immunocompromised patients. The best documented neurological manifestations associ ated with HEV infection are Guillain-Barré syndrome (rapid onset muscle weakness caused by immune mediated damage to the peripheral nervous system), neuralgic amyotrophy (neurological disorder character ized by nerve damage and muscle atrophy), encephalitis (inflammation of the brain) and myelitis (inflammation of the white and grey matter of the spinal cord) 153 . The association between HEV infection and Guillain-Barré syndrome is supported by three casecontrol studies from the Netherlands 156 , Bangladesh 157 and Japan 158 that show evidence of very early HEV infec tion in 5-11% of patients with Guillain-Barré syndrome; this number was significantly higher than in healthy controls. In addition, a Belgian cohort study showed that 6 out of 73 (8%) patients with Guillain-Barré syndrome had evidence of HEV infection 159 . Most of the cohort studies and case studies of HEV infection in patients with neuralgic amyotrophy are from Europe in the context of HEV3 infection 153 . In a cohort study conducted in the Netherlands and United Kingdom, 5 out of 47 (10.6%) patients with neural gic amyotrophy had evidence of HEV infection at the start of their illness 160 . A multicentre study in Europe involving >100 patients with neuralgic amyotro phy showed that patients with HEVassociated neural gic amyotrophy have a distinct clinical phenotype com pared with that of patients with neuralgic amyo trophy who do not have evidence of HEV infection. They were significantly more likely to have bilateral involve ment of the brachial plexus, moreextensive damage to the brachial plexus and neurological damage outside the Nature Reviews | Disease Primers brachial plexus, particularly involvement of the phrenic nerve 160 . A European multicentre study, which prospec tively tested >450 consecutive patients with acuteonset nontraumatic neurological injury, showed evidence of HEV infection in 2.4% of individuals, three of whom had neuralgic amyotrophy with bilateral involvement 161 . Twelve cases of HEV infection and encephalitis and/or myelitis have been reported in Europe, Asia and the United States 153 . Some individuals showed features of additional involvement of the peripheral nervous system. Five individuals were immunocompromised following SOT and had chronic HEV3 infection. Several of these patients had a prominent ataxic component to their neurological symptomatology. These patients had a poor outcome, with longterm neurological sequelae and two deaths. In one of these patients, 'quasispecies compartmentalization' was noted 162 , meaning that HEV quasispecies differed between serum and cerebrospinal fluid, which raises the question of whether some strains of HEV might be neurotropic.
In all these studies, the patients with HEVassociated neurological manifestations generally had normal to modestly abnormal liver function and were mostly anicteric. Thus, the neurological symptoms and signs dominate the clinical picture in these patients 153 . Pathogenetic mechanisms of the neurological manifes tations are uncertain but could be the consequence of molecular mimicry, which would be congruent with current pathophysiological notions in Guillain-Barré syndrome and neuralgic amyotrophy or could be the consequence of direct neurotropism. The relation ship between HEV infection and neurological damage seems causal, at least in the case of Guillain-Barré syn drome, neuralgic amyotrophy, encephalitis and mye litis 153 . The evidence to support causality includes the number and homogeneity of cases over time and geo graphical location, case-control data in Guillain-Barré syndrome, docu mentation of HEV RNA in the serum and cerebrospinal fluid in some cases with quasispecies compartmentalization 162 , presence of antiHEV IgM in cerebrospinal fluid 163 in some cases, resolution of neuro logical symptoms with viral clearance in some cases 164 , in vitro data showing that HEV can grow in a range of neurological cell lines 104, 165 and in vivo studies showing that HEV can cross the blood-brain barrier 166 .
Renal manifestations. Impaired renal function has been observed in both acute and chronic HEV infec tion 167, 168 . Renal biopsy samples from patients infected with HEV1 and HEV3 show evidence of glomerular disease patterns 168, 169 , including membranoproliferative glomerulonephritis with or without cryoglobulinaemia and membranous glomerulonephritis 168, 170, 171 . Flares of preexisting IgA nephropathy have also been observed in patients infected with HEV 168, 172 . Recently, HEV RNA was detected in the cryoprecipitate from serum of an immunocompetent patient with acute HEV infection who presented with cryoglobulinaemic membrano proliferative glomerulonephritis 171 . The clearance of HEV (either spontaneously, after immunosuppressive therapy dose reduction or after antiviral therapy) was associated with an improvement in renal function and a decline in the proteinuria level in most patients 168, 171, 172 . Hence, HEV screening might be recommended in patients with hepatitis who have impaired renal function or proteinuria.
Screening
The high frequency of viraemic blood donors has made HEV infection an issue of concern in the blood trans fusion community. Several countries have introduced universal, targeted or partial screening for HEV in donor blood (TABLE 2) . However, no HEV screening is performed in organ donors.
The screening methodology of choice includes testing for the presence of HEV RNA, as infected blood donors usually have normal liver function tests and are often • Presence of monoclonal immunoglobulin: importance is uncertain, but it was reported in 25% of individuals presenting with acute hepatitis E in a UK study 155 • Thrombocytopenia: mainly mild but occasionally severe 
Prevention
Prevention strategies for waterborne genotypes HEV1 and HEV2 have focused on reducing the risk of exposure through improvements in potable drinking water and sanitation in endemic areas 40, 174 . During an HEV out break, improvement of water quality, often through boil ing or chlorination, results in rapid declines in disease incidence. Conversely, failure to chlorinate the water supply has led to some of the largest documented HEV epidemics 11 . Although HEV1 and HEV2 transmission via shellfish or farm produce is low, safe food handling and cooking might be relevant to prevent infections. The WHO has published specific guidelines to prevent waterborne HEV infection 24 . HEV3 and HEV4 transmission has been largely food borne and linked to the consumption of infected organ meats, game and shellfish. Infections can be prevented by careful preparation of these foods. HEV present in contaminated meat is resilient to lowtemperature cooking (~56 °C) typical of mediumtorare cooking conditions in restaurants 175 . Up to 20 minutes of heating to internal temperatures of 70 °C is deemed necessary to inactivate HEV 176 . In vitro data showed that heating for >2 minutes at 70 °C eliminates HEV infectivity, whereas infective HEV could be detected despite stor age at room temperature after 28 days 177 . In the environ ment, the virus might be more heatlabile at slightly lower temperatures 178 . Minimizing the risk of HEV infections in individuals at risk seems reasonable. For example, immunosuppressed individuals should avoid eating raw meat. Hunters and butchers should avoid intensive, direct contact with pigs and wild boar and/or wear gloves 179 . The silver lining for hepatitis E prevention remains the commercial availability of a highly effective (>99%) threedose vaccine for the prevention of HEV infec tion 131 . The HEV 239 vaccine (Hecolin, Xiamen Innovax Biotech CO, China) demonstrated crossprotection for both HEV1 and HEV4 and was developed to elicit pro tective antibodies across all HEV genotypes 180 . Although licensed for sale and use in China since 2012, the HEV 239 vaccine is not yet available for routine or emergency use in endemic areas. Modelling studies of antibody per sistence suggest longlasting protective immunity that persists for up to 30 years after vaccination 181 . In 2014, the 30th Global Advisory Committee on Vaccine Safety of the WHO reviewed the HEV 239 vaccine, and although reassured by the safety in phase I, II and III trials, a phase IV trial was recommended, and further data on its safety in paediatric, elderly and other special populations was deemed necessary 182 .
Management

Acute hepatitis E
In most immunocompetent individuals, acute hep atitis E does not require antiviral therapy with ribavirin, as HEV infection is spontaneously cleared. Whether early treatment with ribavirin hastens viral clearance or minimizes the risk of liver failure remains to be deter mined. In acute hepatitis B, early antiviral treatment can prevent progression of severe acute hepatitis to acute liver failure 183 and can shorten the course of liver disease 184 . Early treatment of acute hepatitis C is also associated with a rapid normalization of liver function parameters 185 . A small number of individuals with acute hepatitis E have been treated with ribavirin 186, 187 , most of whom were infected with HEV3; two patients were infected with HEV1 (REFS 188, 189) . A rapid normaliza tion of liver enzymes was noted, and all patients rapidly cleared HEV RNA. However, these data are uncontrolled and are based on a highly variable dose and duration of ribavirin therapy. Thus, spontaneous improvement cannot be ruled out. Corticosteroids might decrease the risk of progression to liver failure in patients with fulmin ant hepatitis E. In single cases, corticosteroid therapy was associated with improvement of liver function 134 .
Patients on immunosuppressive therapy
In SOT recipients who receive immunosuppressive therapy, a reduction of immunosuppressive therapy, especially of drugs targeting T cells (such as calcineu rin inhibitors), is considered the firstline therapeutic option 150 (FIG. 6) . Approximately onethird of patients achieve viral clearance after reduction of the dose of the immunosuppressive drugs 141, 150 . Ribavirin treatment might have a role in the manage ment of immunocompromised patients with hepatitis E. A multicentre retrospective study involving 59 patients who received SOT and were treated with ribavirin only at a median dose of 600 mg per day for 3 months showed a sustained virological response (that is, undetectable HEV RNA levels in blood 6 months after completion of ribavirin therapy) in 78% of patients 190 . Individuals who relapsed were additionally treated with ribavirin for 6 months, which led to viral clearance 190 . No difference in sustained virological response was observed between patients who received ribavirin for ≤3 months and those who were given therapy for >3 months 190 . However, the optimal duration of ribavirin therapy is still unknown. Persistence of HEV RNA in the faeces at the end of riba virin therapy in patients with undetectable HEV RNA in the serum is associated with higher risk of HEV relapse after ribavirin cessation 123 . Finally, a decrease in HEV RNA concentration ≥0.5 log 10 at day 7 was also a pre dictive factor for a sustained virological response 191 . Interestingly, no association between ribavirin trough level at day 7 or at 2 months after starting therapy and sustained virological response was observed 191 . Ribavirin and mycophenolic acid (an immuno suppressive drug that inhibits inosine dehydrogenase) have a synergistic effect on suppressing HEV replication in vitro 192 , but the slope of HEV RNA concentration does not differ between patients given ribavirin with or with out mycophenolic acid 191 . Deep sequencing has identi fied several HEV RNA mutations leading to ribavirin resistance, such as G1634R 120, 121, 193, 194 . Ribavirin increases HEV quasispecies heterogeneity, which seems to be reversible 120, 121, 193, 194 . However, the role of HEV RNA variants and their impact on HEV treatment outcome are uncertain 120, 121, 195 . A 3month course of IFNα achieved sustained viro logical response in a few liver transplant recipients and in a patient with chronic HEV infection who was under going haemodialysis [196] [197] [198] . However, IFNα is not recom mended in patients who have received SOT because it stimulates the immune system and increases the risk of acute rejection 199 . Thus, ribavirin therapy has mainly been used for treating chronic HEV infection 188, 190, 200, 201 . An important question to address when faced with an immunocompromised patient with chronic HEV infec tion is when to start HEV treatment. When feasible, immunosuppressive therapy should be reduced as soon as HEV infection is diagnosed. If HEV replication per sists beyond 3 months, ribavirin therapy should be con sidered (FIG. 6) . IFNα therapy is restricted to those who do not respond to ribavirin.
The treatment of chronic HEV infection in immuno suppressed patients have not received SOT has been docu mented in a few case reports and small series. Indeed, pegylated IFNα, ribavirin or the combination of both was effective for treating HEV infection in patients with haematological disease receiving chemo therapy [202] [203] [204] or patients who were HIVpositive 164, 205, 206 . Nine out of twelve individuals who underwent stem cell transplantation and were treated with ribavirin achieved a sustained virological response 204 .
Quality of life
Most HEV infections globally are subclinical 9, 207 . Chronic infections are rare and described only for infections with HEV3 and HEV4 (TABLE 1) . Longterm compli cations in these patients have not been documented. Whether infection confers lifelong or even persistent immunity is unclear 208 . Importantly, infections with HEV1, HEV2, HEV3 or HEV4 can be lifethreatening in immunocom pe tent individuals, pregnant women and immuno compromised patients. In immunocompro mised patients, infection can be chronic. Increased rates of chronic hep atitis after a transplantation have been reported in patients with HEV infection 139 . Finally, sequelae from neurological disorders and encephalitis to fulminant liver failure may occur if the infection is not adequately controlled 154 .
Outlook
Our understanding of HEV has changed completely in the past 10 years. HEV was previously considered to be a waterborne pathogen that mainly caused disease in resourcepoor settings. We now know that HEV is also endemic in many developed countries, where it is largely locally acquired, anthropozoonotic and causes both acute and chronic infection. Because the infection is common and often symptomatic, it has found its way in to the human blood supply, and viraemic donors are surprisingly frequent in many countries in Europe. Whether and how donors should be screened for HEV remains a topic of debate in the blood transfusion com munity. The WHO has established guidelines to prevent waterborne HEV transmission in developing countries. In high income countries, the presence of HEV in the food chain may result in the spread of the virus. Changes in animal farming and food preparation practices to min imize the burden of viable HEV in human food are an important future goal. The implementation of the vaccin ation of animals and humans in endemic areas should be considered in the future.
Our understanding of the biology of HEV is incom plete. As robust cell culture systems and animal models have become available, much progress is anticipated in the next few years. We now have better tools for the diagnosis and genotyping of current and previous HEV infections, and their systematic use in patients with biochemical evidence of hepatitis will help our under standing of the epidemiology and clinical consequences of HEV infection. Indeed, the global burden of HEV is unknown. The most recent figure is an underestimate, as it uses data from 2005 from a limited number of develop ing countries and has not considered the para digm shift in the current thinking of HEV as a global pathogen. The use of PCR assay to detect HEV RNA has recently been harmonized to a WHO standard. Some questions regarding sensitivity and specificity of sero logical assays remain, which will be addressed by estab lishing properly validated WHO reference materials, a project that is currently in progress.
The use of the HEV 239 vaccine is currently limited to China. Efforts are underway, via the WHO, to enable its use in areas of pressing need, such as in the recent outbreak in northeastern Nigeria. No alternative vaccines are in the development pipeline, which perhaps reflects the longstanding neglect of HEV as a pathogen of human significance. Now that we know HEV is endemic in many developed and developing countries, perhaps this mistaken view will start to change.
Whether ribavirin should be administered to immu no competent individuals with hepatitis E requires investigation, as does the optimal management of immuno compromised patients. In vitro data show that calcineurin inhibitors (that is, tacrolimus and cyclo sporine A) and mechanistic target of rapa mycin (mTOR) inhibitors promote HEV replication 192, 209 . Conversely, mycophenolic acid does not 192 , suggesting that myco phenolic acid is preferable in patients who are HEV positive and require SOT 210 . Currently, no effective anti viral drug against HEV apart from ribavirin is available.
In vitro, HEV replication was modestly inhibited by sofosbuvir, a directacting drug that inhibits hepatitis C virus replication by targeting the RNAdependent RNA polymerase NS5B protein 211, 212 . The combination of sofosbuvir and ribavirin lowered viral load in a patient who acquired temporal ribavirin nonresponse; viral load relapsed after terminating the therapy 213 . Thus, the effect of sofosbuvir on HEV replication remains uncertain 214 . The clinical phenotypes of HEV infection in humans are still emerging. It is now clear that HEV can cause a number of extrahepatic manifestations and in particular a range of neurological injuries. The range, frequency and mechanisms of HEVassociated neurological injury is still uncertain. In another 10 years, we may have a much clearer idea about many of these aspects of HEV, which is proving to be one of the more successful zoonotic viruses currently affecting humans.
